Tisotumab Vedotin – The Cancer Killer

Cancer is one of the most prevalent diseases that patients suffer from across the globe. It could be blood cancer, breast cancer, mouth cancer, or any other kind of cancer. While there have been a lot many experiments that have been conducted over the years to help treat cancer patients, none of them have proven to kill the cancer cells completely from the body. But recently, a novel cancer drug known as “Tisotumab Vedotin” has been found which can destroy tumours from within the body. This drug has shown promising results across six different forms of cancer! These included advanced drug-resistant cancers, cervical cancers, lung cancers, bladder cancers, and ovarian cancers. This is possible because the drug releases a toxic substance to kill cancer cells from within. With the success of this drug, it has now been moved forward to the Phase-II trials, where it will be further tested in a range of additional cancer types like head, neck, bowel, pancreatic, and squamous cell lung cancers.

The Phase-I trial included 150 patients who had various kinds of cancer, but had stopped responding to standard treatments. The trial had initially recruited only 27 patients to check for the safety of the drug and establish its right dose, and then expanded to 150 patients to check if the drug was targeting the right patients and goal, and to also check its outcomes. The majority of patients tested in this initial trial included those with advanced stage cancer, and the bodies of whom had become resistant to an average of three different types of treatments. But, when the patients were treated with Tisotumab Vedotin, 27% patients with bladder cancer and cervical cancer, 14% patients with ovarian cancer, 13% patients with lung cancer and esophageal cancer, and 7% patients with endometrial cancer responded positively to it. And, these responses lasted for quite some time, ranging between 5 to 10 months.

The positivity has been observed because of the drug being made up of a toxic substance that is attached to the tail end of an antibody, and designed to seek out a receptor called tissue factor that is present at high levels on the surface of many cancer cells, and linked with worse survival. This tissue factor draws the drug inside the cancer cells, within which the drug kills the cells. The mechanism of action of this drug is completely different and unusual – it sneaks into the cancer cells and kills them from within.

With the experiments the drug has gone through, it clearly shows that the drug has the potential to treat a large number of different types of cancer, especially those with very poor survival rates. All these experiments that are done are no piece of cake. It requires a lot of caution, prudence, and judiciousness, and most importantly a qualified education. One place where such appropriate and legitimate education and skill is offered to clinical research aspirants by qualified professionals is Avigna Clinical Research Institute, where flexible and certified online clinical research courses are offered that students can learn from anywhere and anytime conveniently without compromising on their current jobs and responsibilities.